Inactive Instrument

Press Releases Biovica International AB (publ) Nasdaq Stockholm

Equities

Biovica saves SEK 30 million year and investigates new go-to market model in US	Apr. 24	AQ
Biovica saves SEK 30 million/year and investigates new go-to market model in US	Apr. 23	AQ
Biovica - DiviTum TKa in observational trial	Apr. 15	AQ
DiviTum TKa in Observational Trial	Apr. 15	AQ
DiviTum® TKa in observational trial	Apr. 12	AQ
Nomination Committee for Biovica International AB for the 2024 Annual General Meeting	Apr. 11	AQ
Biovica receives positive patent notification for immunotherapies	Mar. 19	AQ
Biovica - Commercial progress despite a quarter with modest sales	Mar. 18	AQ
Q3 Interim Report November-January 2023/2024	Mar. 14	AQ
Interventional DiviTum® TKa trial launches at Washington University	Mar. 13	AQ
Biovica signs master service agreement	Mar. 12	AQ
Biovica signs master service agreement for TKa testing with leading pharma company	Mar. 07	AQ
Biovica signs agreement with Palex Group, a market leader in Spain and Portugal	Jan. 22	AQ
Biovica signs agreement with Palex Group, a market leader in Spain and Portugal	Jan. 19	AQ
BIOVICA ANNOUNCES OUTCOME OF THE RIGHTS ISSUE	Dec. 14	AQ
DiviTum® TKa in three posters at the world's largest breast cancer symposium	Dec. 05	AQ
Biovica receives license for Maryland state	Dec. 01	AQ
Biovica - Approaching increasing recurring revenues	Nov. 30	AQ
BIOVICA PUBLISHES PROSPECTUS IN CONNECTION WITH THE COMPANY'S PARTIALLY GUARANTEED RIGHTS ISSUE OF APPROXIMATELY SEK 120 MILLION	Nov. 28	AQ
Q2 Interim Report August-October 2023/2024	Nov. 28	AQ

No results for this search